David A. Siegel Regeneron Pharmaceuticals, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 900 shares of REGN stock, worth $646,335. This represents 0.0% of its overall portfolio holdings.
Number of Shares
900
Previous 1,000
10.0%
Holding current value
$646,335
Previous $1.05 Million
9.99%
% of portfolio
0.0%
Previous 0.0%
Shares
25 transactions
Others Institutions Holding REGN
# of Institutions
1,533Shares Held
83.6MCall Options Held
1.22MPut Options Held
1.51M-
Vanguard Group Inc Valley Forge, PA9.32MShares$6.69 Billion0.18% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$6.07 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY7.49MShares$5.38 Billion0.64% of portfolio
-
State Street Corp Boston, MA4.9MShares$3.52 Billion0.21% of portfolio
-
Capital World Investors Los Angeles, CA4.3MShares$3.09 Billion0.72% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $77B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...